The efficacy of boosters against COVID-19 is likely to decline over the next few months and people may need another shot in the fall of 2022, Moderna Inc Chief Executive Officer Stephane Bancel said at a Goldman Sachs-organized health-care conference on Thursday.
Bancel said the company is working on a vaccine candidate tailored to the Omicron variant of the coronavirus, but is unlikely to be available in the next two months.
Get breaking National news
“I still believe we’re going to need boosters in the fall of ’22 and forward,” Bancel said.
- Celine Dion returns to the stage after 6 years at Paris residency: ‘I missed this’
- Trump calls on Ukraine to stop strikes on Russian diesel citing global shortage
- At least 129 missing, 6 dead after ferry overturns in Indonesia’s Java sea
- Turkish authorities launch crackdown on LGBTQ+, HIV support groups
His comments on needing a fourth shot come on the back of Israeli Prime Minister Naftali Bennett citing a study on Tuesday that a fourth dose of COVID-19 vaccine boosts antibodies five-fold a week after the shot is administered.
Moderna, which benefits by repeat inoculations, during its third quarter earnings results said commercial booster market sales could be up to $2 billion in the United States in 2022.
Comments
Want to discuss? Please read our Commenting Policy first.